Streetbeat News

Products Services

PRZO

ParaZero Technologies Ltd. (NASDAQ:PRZO) has received an order from a leading Tier-One defense company for 50 drone safety systems for military operational use. The partnership aims to enhance the efficiency and safety of medical field mission deliveries, particularly in critical and remote areas.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:53 am

PSTV

Plus Therapeutics presented data on its ReSPECT-LM trial of Rhenium Obisbemeda in leptomeningeal disease at the 2024 Society for NeuroOncology/American Society for Clinical Oncology CNS Metastases Conference.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:32 am

BLDP

GOLD

HD

HE

KEY

MNDY

QQQ

SPY

WMT

Nasdaq and S&P 500 futures climbed after a volatile week, with traders focusing on upcoming inflation data and retail earnings from Home Depot and Walmart. KeyCorp shares rose due to Scotiabank's minority stake purchase, while Hawaiian Electric fell after raising a going concern warning. Ballard Power Systems, Barrick Gold, and Monday.com are set to report earnings. The VIX held below 21, and geopolitical tensions rose with Hezbollah's rocket attacks on Israel.

Portfolio Pulse from Shanthi Rexaline

August 12, 2024 | 11:31 am

ABEO

Abeona Therapeutics has concluded a Type A meeting with the FDA to align on the upcoming BLA resubmission for Pz-cel. The company continues to expect to resubmit the BLA in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:31 am

AZN

CDT

Conduit Pharmaceuticals has selected initial indications for its lead clinical candidate, HK-4 Glucokinase Activator AZD1656, licensed from AstraZeneca. Conduit plans to initiate Phase 2a clinical trials to evaluate AZD1656 for the treatment of systemic lupus erythematosus and ANCA-associated vasculitis. Originally developed by AstraZeneca for diabetes mellitus, AZD1656 has undergone extensive safety testing. Conduit aims to leverage its safety profile and targeted mechanism to address autoimmune disorders.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:27 am

MPU

Mega Matrix Corp. (NYSE:MPU) announced that its short drama streaming platform, FlexTV, has ranked No.3 in the App Store Entertainment Chart and Google Play Entertainment App in Indonesia. This achievement highlights FlexTV's strong position in the Asian market and its growing global popularity.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:21 am

SPNS

Sapiens has announced a new contract for its Sapiens ReinsurancePro solution with Society Insurance. The terms of the contract were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:19 am

SNDX

Syndax Pharmaceuticals announced the publication of data from the Phase 2 portion of the AUGMENT-101 trial of Revumenib in adult and pediatric patients with relapsed/refractory KMT2A-rearranged Acute Myeloid Leukemia and Acute Lymphoid Leukemia in the Journal of Clinical Oncology.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:09 am

ASND

The FDA has approved Ascendis Pharma's Yorvipath (Palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. Ascendis is finalizing the manufacturing process for the U.S. market and expects the initial supply to be available in Q1 of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:05 am

DOV

Dover (NYSE:DOV) has acquired SPS Cryogenics B.V. and Special Gas Systems B.V., integrating them into its OPW Clean Energy Solutions business within the Clean Energy & Fueling segment. The terms of the acquisition were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:04 am